- Home
- BLFS vs MDXG Comparison
BLFS vs MDXG Comparison
Compare BLFS & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- MDXG
- Stock Information
- Founded
- BLFS 1987
- MDXG 2006
- Country
- BLFS United States
- MDXG United States
- Employees
- BLFS N/A
- MDXG N/A
- Industry
- BLFS Medical/Dental Instruments
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- MDXG Health Care
- Exchange
- BLFS Nasdaq
- MDXG Nasdaq
- Market Cap
- BLFS 1.2B
- MDXG 1.1B
- IPO Year
- BLFS 1989
- MDXG N/A
- Fundamental
- Price
- BLFS $27.02
- MDXG $9.48
- Analyst Decision
- BLFS Strong Buy
- MDXG Strong Buy
- Analyst Count
- BLFS 7
- MDXG 5
- Target Price
- BLFS $28.29
- MDXG $12.00
- AVG Volume (30 Days)
- BLFS 406.1K
- MDXG 781.2K
- Earning Date
- BLFS 11-12-2024
- MDXG 10-30-2024
- Dividend Yield
- BLFS N/A
- MDXG N/A
- EPS Growth
- BLFS N/A
- MDXG N/A
- EPS
- BLFS N/A
- MDXG 0.52
- Revenue
- BLFS $146,957,000.00
- MDXG $342,804,000.00
- Revenue This Year
- BLFS N/A
- MDXG $9.56
- Revenue Next Year
- BLFS N/A
- MDXG $9.19
- P/E Ratio
- BLFS N/A
- MDXG $18.28
- Revenue Growth
- BLFS 16.40
- MDXG 10.93
- 52 Week Low
- BLFS $14.50
- MDXG $5.47
- 52 Week High
- BLFS $28.88
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- BLFS 58.39
- MDXG 62.95
- Support Level
- BLFS $26.06
- MDXG $9.07
- Resistance Level
- BLFS $28.35
- MDXG $10.14
- Average True Range (ATR)
- BLFS 1.06
- MDXG 0.31
- MACD
- BLFS 0.01
- MDXG -0.11
- Stochastic Oscillator
- BLFS 65.63
- MDXG 41.67
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.